Strategic Investment was led by WuXi AppTec’s Corporate Venture Fund, with participation from Pavilion Capital (a subsidiary of Temasek Holdings), BOLD Capital and Juvenescence


BALTIMORE, Maryland & SHANGHAI, China – June 11, 2018 / PRNewswire/ -- Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, announces the completion of a strategic round of funding led by WuXi AppTec ’s Corporate Venture Fund.  The strategic investment was conditional upon the successful experimental validation of Insilico Medicine’s Generative Adversarial Networks (GAN) and Reinforcement Learning (RL)-based drug discovery pipeline and is intended to closely integrate the cutting-edge artificial intelligence of Insilico Medicine and strength of the laboratory infrastructure and expertise in medicinal chemistry of WuXi AppTec.


The round was led by WuXi AppTec’s Corporate Venture Fund and includes Pavilion Capital, a subsidiary of Temasek Holdings, and BOLD Capital Partners, the venture capital fund investing in exponential technologies co-founded by Peter Diamandis.  Juvenescence Limited, a leading longevity therapeutics company, which partnered with Insilico Medicine on drug discovery also participated in the round.


“WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company and it has been a privilege to work hand in hand with WuXi AppTec’s top synthetic and medicinal chemists and biologists, who routinely solve some of the most complex challenges presented by the global pharmaceutical industry,” said Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine.  “We are fortunate to partner with WuXi AppTec and a consortium of internationally renowned investors with deep domain expertise both in drug discovery and artificial intelligence, validating our approach and supporting our vision.”


The funding is intended to enhance Insilico Medicine’s work in the innovative approaches to the generation of novel molecules using a variety of machine learning and deep learning techniques and expansion of the biomarker discovery initiatives.


“WuXi AppTec and Insilico Medicine have built a close relationship over the past year with a mutual vision that artificial intelligence and machine learning will make the drug discovery process more efficient by increasing the probability of success at the pre-clinical level," said Dr. Ge Li, Chairman of WuXi AppTec Group. "We have experienced first-hand how Insilico Medicine's domain expertise in artificial intelligence and deep neural networks, along with WuXi AppTec's capability platform, can significantly impact drug discovery and eventually fulfill our dream that every drug can be made, every disease can be treated.”


The transaction has been a joint effort between WuXi AppTec’s Corporate Venture Fund and WuXi AppTec’s Research Services Division, which has been focused on investing in and collaborating with highly-disruptive technologies and companies globally.


“With the investment in Insilico Medicine, we are now taking our partnership to the next level by establishing a closer integration within WuXi AppTec’s own research capabilities to better serve the biopharmaceutical industry,” said Mr. Edward Hu, Chief Financial Officer and Chief Investment Officer of WuXi AppTec.  “We have been looking to collaborate with artificial intelligence-enabled technologies to enhance the drug discovery and development process.  What impressed us the most about Insilico Medicine was the breadth of its technological capabilities and applications, ranging from target identification and small molecule generation using next-generation artificial intelligence to expertise in blockchain and aging research.”


DLA Piper (Matthew Gorra and Jay Buchanan) is serving as legal counsel to Insilico Medicine.


For more information on Insilico Medicine, please visit


About WuXi AppTec Co., Ltd.

WuXi AppTec (603259, SH) is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi AppTec is committed to enabling innovative collaborators to bring innovative healthcare products to patients, and to fulfilling WuXi’s dream that “every drug can be made and every disease can be treated.”


Pavilion Capital Pte. Ltd.

Pavilion Capital, a wholly-owned subsidiary of Temasek Holdings, is a Singapore-based investment firm which is focused on private equity investments in North Asia.


About BOLD Capital Partners

BOLD Capital Partners ("BOLD"), is a venture capital firm targeting investments in early stage and growth technology companies. BOLD is particularly interested in entrepreneurial leaders that leverage exponential technologies to transform the world and create innovative solutions to humanities' grand challenges. The investment platform leverages the resources of Singularity University ( and the Peter Diamandis ecosystem ( to actively seek and support world-class entrepreneurs. BOLD has offices in Santa Monica and Palo Alto, California.


About Juvenescence Limited

Juvenescence Limited is a biotech company focused on therapies to increase healthy human longevity. It was founded in 2017 by Jim Mellon, Dr. Greg Bailey, Dr. Declan Doogan, Anthony Chow, and Alexander Pickett. The Juvenescence team are highly experienced drug developers, and serial entrepreneurs with a track record of success in life sciences and drug development. Juvenescence is focused on developing therapeutics that alter ageing or age-related diseases.


Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of ageing and creates the opportunity to develop therapeutics now that can slow, halt or potentially reverse elements of ageing.


About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.  Insilico Medicine’s work was recently covered by MIT Technology Review China, Nature Medicine, Nature Biotechnology, The Pharmaceutical Journal and many others. The Company is routinely publishing advanced research in peer-reviewed journals and presenting at the major industry conferences.


Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.


In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video:


Media Contacts:


WuXi AppTec

Sunnie Sun

[email protected]


Insilico Medicine

Qingsong Zhu

[email protected]